1. iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression
- Author
-
Noufissa Oudrhiri, Christophe Desterke, Fatima Dkhissi, Lucie Portier, Ali G. Turhan, Frank Griscelli, Annelise Bennaceur-Griscelli, Diana Chaker, Afag Asgarova, Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 (UGSF), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Interactions cellules souches-niches : physiologie, tumeurs et réparation tissulaire, Service de Santé des Armées-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Paul Brousse, Modèles de Cellules Souches Malignes et Thérapeutiques, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Hématologie Moléculaire et Cytogénétique Paul Brousse CHU Paris Sud, Université Paris Sud, Inserm UMRS935, 94800 Villejuif, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC), Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP. Université Paris Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service d'Hématologie biologique [AP-HP Hôpital Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris Sud-Paris Saclay, Institut Gustave Roussy (IGR), National Infrastructure INGESTEM, Université Paris Sud, Université Paris Cité (UPCité), and Département de biologie et pathologie médicales [Gustave Roussy]
- Subjects
Lung Neoplasms ,endocrine system diseases ,Angiogenesis ,[SDV]Life Sciences [q-bio] ,Haploinsufficiency ,Mice, SCID ,Metastasis ,lcsh:Chemistry ,angiogenesis ,Mice ,Cell Movement ,Mice, Inbred NOD ,Basic Helix-Loop-Helix Transcription Factors ,Tumor Microenvironment ,RNA, Small Interfering ,skin and connective tissue diseases ,lcsh:QH301-705.5 ,Spectroscopy ,periostin ,iPSC ,Neovascularization, Pathologic ,BRCA1 Protein ,General Medicine ,Computer Science Applications ,KLF4 ,Disease Progression ,Female ,Stromal cell ,Induced Pluripotent Stem Cells ,Breast Neoplasms ,Biology ,Article ,Catalysis ,Inorganic Chemistry ,Kruppel-Like Factor 4 ,breast cancer ,SOX2 ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,mesenchymal stem cells ,Wound Healing ,Gene Expression Profiling ,Organic Chemistry ,Cancer ,BRCA1 ,medicine.disease ,Xenograft Model Antitumor Assays ,Gene Ontology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Tumor progression ,Cancer cell ,Cancer research ,Transcriptome ,Cell Adhesion Molecules - Abstract
Tumor progression begins when cancer cells recruit tumor-associated stromal cells to produce a vascular niche, ultimately resulting in uncontrolled growth, invasion, and metastasis. It is poorly understood, though, how this process might be affected by deletions or mutations in the breast cancer type 1 susceptibility (BRCA1) gene in patients with a lifetime risk of developing breast and/or ovarian cancer. To model the BRCA1-deleted stroma, we first generated induced pluripotent stem cells (iPSCs) from patients carrying a germline deletion of exon 17 of the BRCA1 gene (BRCA1+/&minus, who, based on their family histories, were at a high risk for cancer. Using peripheral blood mononuclear cells (PBMCs) of these two affected family members and two normal (BRCA1+/+) individuals, we established a number of iPSC clones via non-integrating Sendai virus-based delivery of the four OCT4, SOX2, KLF4, and c-MYC factors. Induced mesenchymal stem cells (iMSCs) were generated and used as normal and pathological stromal cells. In transcriptome analyses, BRCA1+/&minus, iMSCs exhibited a unique pro-angiogenic signature: compared to non-mutated iMSCs, they expressed high levels of HIF-1&alpha, angiogenic factors belonging to the VEGF, PDGF, and ANGPT subfamilies showing high angiogenic potential. This was confirmed in vitro through the increased capacity to generate tube-like structures compared to BRCA1+/+ iMSCs and in vivo by a matrigel plug angiogenesis assay where the BRCA1+/&minus, iMSCs promoted the development of an extended and organized vessel network. We also reported a highly increased migration capacity of BRCA1+/&minus, iMSCs through an in vitro wound healing assay that correlated with the upregulation of the periostin (POSTN). Finally, we assessed the ability of both iMSCs to facilitate the engraftment of murine breast cancer cells using a xenogenic 4T1 transplant model. The co-injection of BRCA1+/&minus, iMSCs and 4T1 breast cancer cells into mouse mammary fat pads gave rise to highly aggressive tumor growth (2-fold increase in tumor volume compared to 4T1 alone, p = 0.01283) and a higher prevalence of spontaneous metastatic spread to the lungs. Here, we report for the first time a major effect of BRCA1 haploinsufficiency on tumor-associated stroma in the context of BRCA1-associated cancers. The unique iMSC model used here was generated using patient-specific iPSCs, which opens new therapeutic avenues for the prevention and personalized treatment of BRCA1-associated hereditary breast cancer.
- Published
- 2021
- Full Text
- View/download PDF